Medtronic to turn Hyderabad into R&D hub with $160.3M investment

Medtronic to turn Hyderabad into R&D hub with $160.3M investment

Published: 9 minutes ago By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company since the past 5 years ....

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s termination of its 35 years of....

Appili gets FDA approval to expand the clinical trial of favipiravir

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application for favipiravir, a bro....

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The trials will be conducted i....

Montero inks agreement to acquire Isabella Gold Silver Project

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration claims on the Isabella Go....

Amazon cleared by UK regulators to buy 16% stake in Deliveroo

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to competition. In May o....

PharmaCyte to submit IND application to FDA for clinical trial in LAPC

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among patients with LAPC (l....

Industry Updates